Literature DB >> 18172610

Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia?

Kyu-Sung Lee1, Hye Won Lee, Deok Hyun Han.   

Abstract

This review discusses the available evidence concerning the use of anticholinergic drugs, alone or in combination with alpha-adrenoceptor antagonists, in men with lower urinary tract symptoms due to benign prostatic hyperplasia, benign prostatic enlargement, or benign prostatic obstruction and concomitant overactive bladder syndrome. We emphasize the safety and efficacy of anticholinergic agents in treating men with benign prostatic obstruction. Several recent studies of men with an overactive bladder suggest that combination therapy of anticholinergic and alpha-adrenoceptor antagonists improves the symptoms effectively without increasing the incidence of acute urinary retention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18172610     DOI: 10.1007/s00210-007-0242-y

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  71 in total

1.  Alpha antagonists-from initial concept to routine clinical practice.

Authors:  Christopher Chapple
Journal:  Eur Urol       Date:  2006-07-26       Impact factor: 20.096

2.  Urinary symptoms in the community: how bothersome are they?

Authors:  J V Jolleys; J L Donovan; K Nanchahal; T J Peters; P Abrams
Journal:  Br J Urol       Date:  1994-11

3.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

Authors:  Debra E Irwin; Ian Milsom; Steinar Hunskaar; Kate Reilly; Zoe Kopp; Sender Herschorn; Karin Coyne; Con Kelleher; Christian Hampel; Walter Artibani; Paul Abrams
Journal:  Eur Urol       Date:  2006-10-02       Impact factor: 20.096

4.  alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it.

Authors:  C Rossi; B B Kortmann; G S Sonke; D L Floratos; L A Kiemeney; H Wijkstra; J J de la ROSETTE
Journal:  J Urol       Date:  2001-01       Impact factor: 7.450

5.  Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo.

Authors:  S S Hegde; A Choppin; D Bonhaus; S Briaud; M Loeb; T M Moy; D Loury; R M Eglen
Journal:  Br J Pharmacol       Date:  1997-04       Impact factor: 8.739

6.  Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.

Authors:  Ji Youl Lee; Hyun Woo Kim; Seung Ju Lee; Jun Sung Koh; Hong Jin Suh; Michael B Chancellor
Journal:  BJU Int       Date:  2004-10       Impact factor: 5.588

7.  The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction.

Authors:  Michel A Pontari; Alan S Braverman; Michael R Ruggieri
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2004-01-29       Impact factor: 3.619

8.  Prevalence and burden of overactive bladder in the United States.

Authors:  W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein
Journal:  World J Urol       Date:  2002-11-15       Impact factor: 4.226

9.  Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats.

Authors:  Petter Hedlund; Tomi Streng; Tack Lee; Karl-Erik Andersson
Journal:  J Urol       Date:  2007-05-15       Impact factor: 7.450

10.  The effect of terazosin on bladder function in the spinal cord injured patient.

Authors:  S J Swierzewski; E A Gormley; W D Belville; P M Sweetser; J Wan; E J McGuire
Journal:  J Urol       Date:  1994-04       Impact factor: 7.450

View more
  2 in total

1.  The muscarinic receptor antagonist propiverine exhibits α(1)-adrenoceptor antagonism in human prostate and porcine trigonum.

Authors:  Melinda Wuest; Lambertus P Witte; Martina B Michel-Reher; Stefan Propping; Manfred Braeter; Gerhard J Strugala; Manfred P Wirth; Martin C Michel; Ursula Ravens
Journal:  World J Urol       Date:  2011-02-19       Impact factor: 4.226

2.  Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction.

Authors:  Petros Sountoulides; Marleen M van Dijk; Hessel Wijkstra; Jean J M C H de la Rosette; Martin Christian Michel
Journal:  World J Urol       Date:  2009-10-09       Impact factor: 4.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.